OpenAI Launches GPT-Rosalind — First Specialized Life Sciences Model for Drug Discovery and Genomics
OpenAI Blog·high signal
OpenAI introduced GPT-Rosalind, a frontier reasoning model fine-tuned for biochemistry, genomics, protein engineering, and drug discovery workflows. It outperforms GPT-5.4 on 6/11 LABBench2 tasks with significant gains in molecular cloning protocol design. Launch customers include Amgen, Moderna, Allen Institute, and Thermo Fisher Scientific. Named after Rosalind Franklin, it's the first in a planned series of science-specific models — a clear shot at Google DeepMind's AlphaFold dominance in the bio space.